

Long-term results of GH therapy in GH-deficient children treated in Albania

Agim Gjikopulli¹, Lindita Grimci¹, Laurant Kollçaku¹, Sonila Tomori¹, Aferdita Tako¹, Paskal Cullufe¹, Petrit Hoxha¹, Zamira Ylli²

¹ Division of Pediatric Endocrinology, Department of Pediatrics, ²Department of Laboratory, University Hospital Centre "Mother Teresa", Albania

Background

Recombinant human growth hormone, which was approved in 1985, made available a reliable and virtually unlimited resource to replace human pituitary growth hormone. Idiopathic growth hormone deficiency is the main indication for treatment in more than one half of children receiving growth hormone therapy. Growth hormone treatments aim to normalize growth, correct health problems associated with growth hormone deficiency, and help patients achieve an adult height in the normal range for the general population and for familial genetic potential. Long term studies had shown that it was possible to achieve the above objectives in patients who were optimally treated.

In Albania, the use of growth hormone has been increasing slowly since 2001 due to high cost of treatment, lack of funding for patients and lack of public awareness until recently. Moreover, data regarding response to treatment and factors affecting final height in our local population has not been available.

Objective and hypotheses

To evaluate the efficiency of recombinant growth hormone (rhGH) in improving adult height in children with growth hormone deficiency (GHD).

Materials and methods

This is an observational follow up study which enrolled all Albanian children diagnosed with GHD [isolated (IGHD) or multiple pituitary hormone deficiencies (MPHD)] and treated with rhGH, who had attained final height. Patients with syndromes, tumors, other systemic diseases were excluded. Their treatment started between 2001 and 2015. Main outcome measures were: annual changes in height, change in height between the start of treatment and adulthood height and the importance of the factors that influence on final height.

Results were expressed as mean \pm standard deviation (SD). Data was analyzed using the IBM SPSS Statistics Version 20.

Conclusions

Most of our patients with GHD treated with recombinant growth hormone were able to achieve their genetic height potential. Despite starting treatment late, they managed to gain 2.18 ± 1.20 z-scores in height and the final height for majority of them (58.7%) was within the target height range. There was no statistical significance difference between the two main diagnoses, neither in mean of total height gain nor in mean of final (definitive) HAZ-score. It was found that the good Predictors (with greater importance) that had more influence on final height were "duration of treatment with GH"; "age at which GH treatment was started"; "HAZ score at the start of treatment" and the "Pubertal HAZ gain". This study highlighted the importance for early diagnosis and treatment in children with growth hormone deficiency. This is to ensure adequate duration of treatment to optimize the prepubertal growth so that height prognosis of these children can be further improved.

References

- DS Hardin, SF Kemp, DB Allen. Twenty years of recombinant human growth hormone in children: relevance to pediatric care providers. *Clinical Pediatrics* 2007; 46: 4: 279-86.
- Westphal O, Lindberg A. Final height in Swedish children with idiopathic growth hormone deficiency enrolled in KIGS treated optimally with growth hormone. *Acta Paediatr* 2008; 97: 1698-706.
- Reiter EO, Price DA, Wilton P, Albertsson-Wikland K, Ranke MB. Effect of growth hormone treatment on the final height of 1258 patients with idiopathic GH deficiency: analysis of a large international database. *J Clin Endocrinol Metab* 2006; 91: 2047-54.
- de Ridder MA, Stijnen T, Hokken-Koelega AC. Prediction of adult height in growth-hormone-treated children with growth hormone deficiency. *J Clin Endocrinol Metab* 2007; 92: 925-31.
- Ranke MB, Lindberg A, Albertsson-Wikland K, Wilton P. Increased response but lower responsiveness to growth hormone in very young children (0-3 years) with idiopathic GH Deficiency: Analysis of data from KIGS. *J Clin Endocrinol Metab* 2005; 90: 1966-71.
- Cutfield W, Lindberg A, Albertsson WK, Chatelain P, Ranke MB, Wilton P. Final height in idiopathic growth hormone deficiency: the KIGS experience. *KIGS International Board. Acta Paediatr Suppl* 1999; 88: 72-5.
- Mauras N, Attie KM, Reiter EO, Saenger P. High dose recombinant human growth hormone treatment of GH deficient patients in puberty increases near final height: a randomized, multicenter trial. *J Clin Endocrinol Metab* 2000; 85: 3653-60.
- Gary Butler. Indications for growth hormone therapy. *Paediatrics and Child Health* 2007; 17: 9: 356-61.

Results


92 patients, who were treated with growth hormone, had attained adult height. The male/female ratio was 70/22.

37% (34/92) of them had IGHD, while 63% (58/92) had multiple pituitary hormone deficiencies. The mean age of starting GH treatment in our patients was 13.06 ± 2.61 years old, with boys starting treatment later (13.21 ± 2.53 years old) compared to girls (12.58 ± 2.87 years old).

	IGHD	MPHD	Total
Gender	Female (no.)	9	22
	Male (no.)	25	70
Age at starting treatment (years)	13.51 ± 2.13	12.8 ± 2.84	13.06 ± 2.61
HAZ score at start of treatment	-4.59 ± 1.08	-4.10 ± 1.02	-4.28 ± 1.06
Pubertal HAZ gain*	1.99 ± 0.73	1.56 ± 1.07	1.73 ± 0.97
HAZ score gain from start to the end of treatment**	2.47 ± 1.28	2.02 ± 1.13	2.18 ± 1.20
HAZ score at the end of treatment (Final HAZ score)	-2.18 ± 1.45	-2.02 ± 1.16	-2.08 ± 1.27
Duration of treatment (years)	3.73 ± 1.66	3.75 ± 2.16	3.73 ± 1.98
GH dose	0.21 mg/kg/week (nr)	8	29
	0.24 mg/kg/week (nr)	10	54
	0.27 mg/kg/week (nr)	3	9

*Pubertal HAZ gain = (Final HAZ score) - (HAZ score at onset of puberty)

**HAZ score gain = (Final HAZ score) - (HAZ score at start of treatment)



Automatic Linear Regression model was built to assess the importance of the variable on the final height. This model noted out that duration of treatment, age at starting of treatment, HAZ score at start of treatment, HAZ score changes during puberty, gender, and Mid Parental HAZ score affects strongly on final height (Table 2).

Model Term	Coef.	Std. Err.	t	Sig.	95% Confidence Interval		Importance
					Lower	Upper	
Intercept	68.10	16.072	4.237	.000	36.13	100.0	
Duration of treatment	6.454	0.429	15.05	.000	5.602	7.307	0.534
Age at starting treatment	3.556	0.351	10.13	.000	2.858	4.254	0.242
HAZ score at start of treatment	5.303	0.629	8.430	.000	4.052	6.555	0.167
Pubertal HAZ gain	2.934	0.666	3.386	.001	1.211	4.657	0.027
Gender=Female	-4.93	1.849	-2.67	.009	-8.61	-1.25	0.017
Mid Parental HAZ score	0.218	0.091	2.395	.019	0.037	0.399	0.014

